Reflux Sits in the Middle of the Bariatric Decision

Three in ten. That is the share of patients in a new registry analysis who arrived for metabolic and bariatric surgery already carrying a diagnosis of gastroesophageal reflux disease — and most of them received the operation that reflux surgeons discuss most carefully, the sleeve.

The study, in Surgery for Obesity and Related Diseases, draws on the MBSAQIP registry — the accreditation file kept by the American College of Surgeons and ASMBS — for operations performed between 2015 and 2022: 1,282,883 adults having a first sleeve, gastric bypass or duodenal switch. Reflux was recorded in 30.5%.

What an odds ratio of 1.2 does and does not mean

After adjustment for comorbidities, a preoperative GERD diagnosis was associated with higher odds of three 30-day outcomes: infections (odds ratio 1.27), serious complications (1.20) and readmission (1.26). The authors also note that patients with GERD differed in cardiac history in ways they call clinically relevant.

Those are modest relative differences in a retrospective registry, and most patients with reflux had no complication at all. The paper is careful about its exposure: GERD in MBSAQIP is whatever was coded and treated before surgery, which lumps occasional heartburn on a proton pump inhibitor together with erosive disease. Its conclusion is not that reflux should block an operation, but that a coded diagnosis “may warrant enhanced perioperative risk assessment” — a marker for looking harder at the whole patient, not a verdict.

Then comes the line that makes the paper worth reading twice. Sleeve gastrectomy was the most performed procedure among patients with GERD, “despite clinical recommendations favoring RYGB.” The registry cannot say why; case mix, anatomy, surgeon volume, patient preference and insurance are all unmeasured, and the authors do not speculate.

The recommendations behind that sentence

They are not a single rule, and it is worth being precise about what the specialty societies have actually published.

ASMBS’s 2021 position statement on upper endoscopy lists among its rationales the “mucosal abnormalities, including gastroesophageal reflux disease and associated esophageal mucosal injuries (erosive esophagitis and Barrett’s esophagus)” that may develop in the long term after a sleeve or a bypass. That is a surveillance argument, not a prohibition.

IFSO went further in 2020 with an entire position statement on Barrett’s esophagus, built by a task force asked three questions: how common Barrett’s is in people presenting for metabolic surgery, how often it develops afterwards “with a particular focus on the laparoscopic sleeve gastrectomy,” and whether it can regress after surgery. Read together, the two documents make reflux the main long-term esophageal question in this field — and the sleeve the procedure whose esophageal consequences are least settled.

Against that, the practice pattern looks like inertia or pragmatism, depending on whom you ask. A modelling paper from Guangzhou in Obesity Surgery hints at how much disease is found only by looking: of 1,068 candidates assessed before surgery, 26.2% had reflux esophagitis on endoscopy, and a gradient-boosted model on six routine variables reached an AUC of 0.825 — internal validation only, which the authors call insufficient for clinical use.

Repairing the hernia at the same time

If reflux is the problem, one response is to fix the hiatal hernia during the sleeve. A two-centre cohort from Tashkent, published in Obesity Surgery in late September, compares 66 consecutive patients with symptomatic hiatal hernia, all operated by one team, all given a sleeve over a 38 French bougie with posterior crural repair. Thirty-one also had a fundoplication built from the preserved fundus — a Nissen below age 50, a Toupet at 50 and above — and 35 did not.

At 18 months, with endoscopy in every patient, reflux remission (a GERD questionnaire score under 8 without erosive esophagitis) was 96.8% with the wrap versus 65.7% without: a difference of 31.1 percentage points, 95% confidence interval 12.4 to 47.8. Intrathoracic migration occurred in none of the 31 wrapped patients and 8 of the 35 unwrapped — 22.9%. Excess weight loss was 89.1% versus 87.2%. Persistent dysphagia was more frequent after fundoplication, 16.1% versus 2.9%, though it did not reach significance and all cases were mild, without dilation or reoperation.

Two findings deserve emphasis. Hernia size did not identify who could safely skip the wrap: after crural repair alone, recurrence was 33.3% in smaller hernias and 34.6% in larger ones. And allocation was not random — 66 patients, one surgical team, 18 months. That generates a hypothesis, not a standard.

What happens when the pill does the work

The medical alternative got its own small prospective test in Japan. Of 54 consecutive sleeve patients at one centre, 19 developed reflux symptoms within a year; endoscopy found erosive esophagitis in 16, including 11 with no erosive disease beforehand, and the median time to symptoms was 40 days, with a range stretching to 196. Four weeks of vonoprazan, a potassium-competitive acid blocker, at 20 mg daily healed the mucosa in all 16, and symptom scores fell from a median of 28 to 7. No comparator arm, no follow-up beyond the treatment window: the study shows the mucosa can be healed, not that reflux is controlled.

A third paper complicates the picture. In 133 patients who had a cholecystectomy after their sleeve — the standard operation for gallstones that surface during rapid weight loss — endoscopy showed moderate esophagitis rising from 3.0% before the sleeve to 12.2% after the gallbladder operation, severe esophagitis from 0.8% to 2.7%, and gastritis from 33.9% to 51.4%. The design is retrospective with no control group, and repeated scoping over years confounds any trend. But it suggests the lower stomach and the biliary tree may shape esophageal findings too, which makes a single explanation for post-sleeve reflux harder to sustain.

The study nobody has run

What the field still lacks is the obvious one: a prospective cohort in which the operation is chosen with reflux status known in advance, followed with endoscopic rather than questionnaire endpoints, and reported by procedure. The LABS study, funded by NIDDK, is the closest American design precedent — a prospective multi-centre cohort with structured follow-up, documented in this site’s LABS study archive — but it predates the sleeve’s dominance and treated reflux as a baseline comorbidity rather than an outcome.

Until then, the registry describes a steady state: a third of patients arrive with reflux, the adjusted odds of a serious complication run about 20% higher for them, and the operation most of them get is the one whose esophageal future is least well mapped. Yesterday’s analysis of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy found a related asymmetry from the other direction: endoscopic plication produced less reflux than the surgical sleeve in pooled data, at the cost of far less weight loss. Both point at the same unanswered question — how much reflux burden a given amount of weight loss is worth.